市場調查報告書

狂犬病(恐水症)疫苗的全球市場:成長,趨勢,及預測

Rabies Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 704728
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
Back to Top
狂犬病(恐水症)疫苗的全球市場:成長,趨勢,及預測 Rabies Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年09月01日內容資訊: 英文 114 Pages
簡介

本報告提供全球狂犬病(恐水症)疫苗市場的相關調查,市場機會和課題,成長及阻礙因素,各產品類型、疫苗類型、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各產品類型
  • 各疫苗接種類型
    • 暴露前疫苗接種類(PEV)
    • 暴露後疫苗接種類(PEP)
  • 各終端用戶
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • AstraZeneca (MedImmune)
    • Berna Biotech Ltd
    • GlaxoSmithKline
    • Merck & Co Inc
    • Novartis AG
    • Pfizer Inc
    • Sanofi Pasteur, Inc
    • Zoetis Animal Healthcare
    • *清單為例示列舉。

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 62883

Market Overview

Rabies is a viral disease spread by the bite or scratch of an animal, however, the symptoms appear relatively slowly. In such cases, by the time, the symptoms appear, it is generally too late to save the patients. In the developed markets, the cases of human rabies is less because of more pet friendly communities and government initiatives, however, in emerging markets as well as low-income countries, there are fewer regulations to protect the people against animals bites and a large number of stray dogs can be observed across metropolitan cities as well as other cities and towns. Such factors raise the concerns regarding low protection against dog bites which raises the demand for rabies vaccines in such regions. However, limited resources, as well as negligence by government general public, are among the major causes which limit the use and adoption of rabies vaccines.

Scope of the Report

Domestic dogs are among the most common reservoir of viruses, which is regularly being checked by government initiatives adopted well across major cities and region in the world. However, still, several diagnostic tests and vaccines are given to prevent the cases of rabies across humans. The scope of the report covers the rabies vaccines market by product, vaccination type, end-user, and geography.

Key Market Trends

The Purified Chick Embryo Cell Rabies Vaccine is Estimated to Contribute Large, Over the Forecast Period

The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine acts by exposing a small dose of rabies virus to the patient in order to develop immunity to the disease. This vaccine can be used for post-exposure or pre-exposure. Such factors drive their importance and usage across hospitals and clinics.

North America is Estimated to Have Largest Share in the Global Market

According to the data published by Centers for Disease Control and Prevention (CDC) in the United States, wild animals accounted for 92.4% of the rabies cases, whereas domestic animals accounted for 48.7% cases of rabies in 2015. In the past few years, the number of human deaths attributed to rabies in the United States has declined due to two major reasons, the first one is animal control and vaccination programs. Secondly, effective human rabies vaccines and immunoglobulins have been developed over time. Similarly, major steps were taken across Canada and Mexico to protect the animals and humans rabies virus infection spread. A significant contribution by government and companies interests in this regions, makes this region, highly useful in terms of demand and use of rabies vaccines.

Competitive Landscape

The major market players are focusing on technological advancements and pet care initiatives in collabroation with hospitals and government channels. Some of the major players in the market are AstraZeneca (MedImmune), GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, and Cadila Pharmaceuticals Ltd, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Mortality due to Rabies
    • 4.2.2 Large Population of Stray Dogs in Low and Middle Income Countries
    • 4.2.3 Growing Pet Management technological Advancements and Services
  • 4.3 Market Restraints
    • 4.3.1 Low Immunization Rates in Dogs
    • 4.3.2 Lack of Awareness and Negligence by Government and Public
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Baby Hamster Kidney (BHK)
    • 5.1.2 Purified Chick Embryo Cell Rabies Vaccine
    • 5.1.3 Vero Cell Rabies Vaccine
    • 5.1.4 Other Product Types
  • 5.2 By Vaccination Type
    • 5.2.1 Pre-Exposure Vaccination (PEV)
    • 5.2.2 Post-Exposure Prophylaxis (PEP)
  • 5.3 By End User
    • 5.3.1 Animals
    • 5.3.2 Humans
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 France
      • 5.4.2.2 Germany
      • 5.4.2.3 United Kingdom
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca (MedImmune)
    • 6.1.2 Berna Biotech Ltd
    • 6.1.3 GlaxoSmithKline
    • 6.1.4 Merck & Co Inc
    • 6.1.5 Novartis AG
    • 6.1.6 Pfizer Inc
    • 6.1.7 Sanofi Pasteur, Inc
    • 6.1.8 Zoetis Animal Healthcare
    • 6.1.9 * List Not Exhaustive

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top